Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John D. Catt is active.

Publication


Featured researches published by John D. Catt.


Bioorganic & Medicinal Chemistry Letters | 2003

Indanyl piperazines as melatonergic MT2 selective agents

Ronald J. Mattson; John D. Catt; Daniel J. Keavy; Charles P. Sloan; James R. Epperson; Qi Gao; Donald B. Hodges; Lawrence G. Iben; Cathy D. Mahle; Elaine Ryan; Frank D. Yocca

Optimization of a benzyl piperazine pharmacophore produced N-acyl-4-indanyl-piperazines that bind with high affinity to melatonergic MT(2) receptors. (R)-4-(2,3-dihydro-6-methoxy-1H-inden-1-yl)-N-ethyl-1-piperazine-carboxamide fumarate (13) is a water soluble, selective MT(2) agonist, which produces advances in circadian phase in rats at doses of 1-56 mg/kg that are no different from those of melatonin at 1 mg/kg. Unlike melatonin, 13 produced only weak contractile effects in rat tail artery.


Nuclear Medicine and Biology | 1993

Synthesis of (±)-[18F]BMY 14802, its enantiomers and their anatomical distributions in rodents

Chyng-Yann Shiue; Lan-Qin Bai; Grace G. Shiue; Joseph A. Rysavy; Richard C. Pleus; Huang Hui; Mathis P. Frick; John D. Catt

A potential antipsychotic drug, BMY 14802 was labeled with 18F and its distribution in rodents was studied. No-carrier-added (NCA) (+/-)-[18F]BMY 14802 (5) was synthesized by two methods in 5-10% radiochemical yield in a synthesis time of 130-140 min from EOB with a specific activity of 0.5-1.5 Ci/microM. (+)- and (-)-[18F]BMY 14802 was synthesized by the chiral reduction of alpha-(4-[18F]fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine-b utanone (4) with chiral reducing agent, (+)- and (-)-beta-chlorodiisopinocampheylborane [(+)- and (-)-DIP chloride] in 6-10% radiochemical yield in a synthesis time of 150 min from EOB. Animal studies in mouse and in rat revealed that the distribution of 5 in each tissue was high at 5 min, the radioactivity then declined rapidly in all tissues studied except in the liver and in the small intestine. The radioactivity in the femur did not increase with time indicating in vivo defluorination may not occur. The uptakes of (+/-)-[18F]BMY 14802 and its enantiomers, (+)- and (-)-[18F]BMY 14802 in rat cerebellum, brain stem, hippocampus and spinal cord were similar and were significantly reduced by prior treatment of rat with haldol. This suggests that (+/-)-[18F]BMY 14802 and its enantiomers bind to sigma-receptors in a similar fashion.


Bioorganic & Medicinal Chemistry Letters | 2003

Development of a presynaptic 5-HT1A antagonist.

Ronald J. Mattson; John D. Catt; Charles P. Sloan; Qi Gao; Richard B Carter; Anthony J. Gentile; Cathy D. Mahle; F.Fatima Matos; Rachel T. McGovern; Cam VanderMaelen; Frank D. Yocca

A new 5-HT(1A) silent antagonist 14 (5-HT(1A) IC(50)=2.2 nM) antagonizes the effects of agonists on reciprocal forepaw treading behavior, on neuronal firing in the rat dorsal raphé, and on 5-HT(1A) release in the raphé and hippocampus. While 14 alone was inactive in the social interaction paradigm, it completely reversed the social interaction activity of the serotonergic compounds (buspirone, 1, and 2).


Heterocycles | 2001

Preparation of heterocyclic enamines. Useful intermediates in the synthesis of 1,4-dihydropyridines

Graham S. Poindexter; John D. Catt; Philip A. Sasse; Michele A. Kercher

Various heterocycles (4,5-dihydrooxazoles, 4,5-dihydro-4H-oxazines, and tetrazoles) can be readily metalated and condensed with a variety of organic nitriles to afford heterocyclic enamines (2). These enamines can be utilized in Hantzsch condensation reactions to prepare heterocyclic substituted 1,4-dihydropyridines (3) which are unavailable by standard routes


Journal of Medicinal Chemistry | 1986

Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.

Joseph P Yevich; James Stewart New; David W. Smith; Walter G. Lobeck; John D. Catt; Joseph L. Minielli; Michael S. Eison; Duncan P. Taylor; Leslie A. Riblet; Davis L Temple


Archive | 1976

2-Piperazinyl-6,7-dimethoxyquinazolines

William Lesley Matier; John D. Catt


Journal of Medicinal Chemistry | 1990

Synthesis, biological profile, and quantitative structure-activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

Sing-Yuen Sit; Rex A. Parker; I. Motoc; Wen-Ching Han; N. Balasubramanian; John D. Catt; P. J. Brown; W. E. Harte; Thompson; John J Wright


Archive | 1992

Piperazinyl-and piperidinyl-cyclohexanols

Ronald J. Mattson; John D. Catt


Journal of Medicinal Chemistry | 1989

A potent, tissue-selective, synthetic inhibitor of HMG-CoA reductase

N. Balasubramanian; P. J. Brown; John D. Catt; W. T. Han; Rex A. Parker; Sing-Yuen Sit; John J Wright


Journal of Medicinal Chemistry | 2005

Conformationally Restricted Homotryptamines. 2. Indole Cyclopropylmethylamines as Selective Serotonin Reuptake Inhibitors

Ronald J. Mattson; John D. Catt; Derek J. Denhart; Jeffrey A. Deskus; Jonathan L. Ditta; Mendi A. Higgins; Charles P. Sloan; Brett R. Beno; Qi Gao; Melissa A. Cunningham; Gail K. Mattson; Thaddeus F. Molski; Matthew T. Taber; Nicholas J. Lodge

Collaboration


Dive into the John D. Catt's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Qi Gao

Bristol-Myers Squibb

View shared research outputs
Researchain Logo
Decentralizing Knowledge